ETERNA THERAPEUTICS INC (ERNA) Stock Price, Quote, News and Overview
NASDAQ:ERNA - Nasdaq - US1140822099 - Common Stock - Currency: USD
ERNA Quote, Performance and Key Statistics
ETERNA THERAPEUTICS INC
NASDAQ:ERNA (2/5/2025, 8:00:01 PM)
After market: 0.3342 +0.01 (+3.47%)0.323
-0.04 (-10.28%)
The current stock price of ERNA is 0.323 USD. In the past month the price decreased by -2.06%. In the past year, price decreased by -80.49%.
ERNA Latest News, Press Releases and Analysis
These stocks are moving in today's after hours session
Wednesday's after hours session: top gainers and losers
Curious about what's happening in today's session? Check out the latest stock movements and price changes.
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session.
Get insights into the top gainers and losers of Tuesday's after-hours session.
Get insights into the top gainers and losers of Tuesday's after-hours session.
Top movers in Monday's after hours session
Monday's after hours session: top gainers and losers
Eterna Therapeutics Announces Expansion of Scientific Advisory Board
Dr. Jerome Zeldis and Dr. ...
ERNA Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.95 | 338.85B | ||
| AMGN | AMGEN INC | 15.53 | 165.46B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 957.73 | 125.79B | ||
| GILD | GILEAD SCIENCES INC | 22.49 | 124.19B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.7 | 78.76B | ||
| ARGX | ARGENX SE - ADR | N/A | 40.17B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 35.64B | ||
| BNTX | BIONTECH SE-ADR | N/A | 29.34B | ||
| ONC | BEIGENE LTD-ADR | N/A | 24.26B | ||
| NTRA | NATERA INC | N/A | 23.37B | ||
| BIIB | BIOGEN INC | 8.91 | 21.21B | ||
| UTHR | UNITED THERAPEUTICS CORP | 15.55 | 15.81B |
Related stock screener links
About ERNA
Company Profile
Eterna Therapeutics, Inc. engages in the provision of cell engineering therapies. The company is headquartered in Cambridge, Massachusetts and currently employs 8 full-time employees. The firm has in-licensed a portfolio of over 100 patents covering key mRNA cell engineering technologies, including technologies for mRNA cell reprogramming, mRNA gene editing, the NoveSlice and UltraSlice gene-editing proteins, and the ToRNAdo mRNA delivery system (collectively mRNA technology platform). Its mRNA gene-editing technology is designed to delete, insert and repair deoxyribonucleic acid (DNA) sequences in living cells, which may be useful for correcting disease-causing mutations, making cells resistant to infection and degenerative disease, modulating the expression of immunoregulatory proteins to enable the generation of durable allogeneic cell therapies, and engineering immune cells to more effectively fight cancer.
Company Info
ETERNA THERAPEUTICS INC
1035 Cambridge Street, Suite 18A
Cambridge MASSACHUSETTS US
Employees: 8
Company Website: https://eternatx.com/
Investor Relations: https://investor.eternatx.com/
Phone: 12125821199
ERNA FAQ
What is the stock price of ERNA?
The current stock price of ERNA is 0.323 USD.
What is the symbol for ETERNA THERAPEUTICS INC stock?
The exchange symbol of ETERNA THERAPEUTICS INC is ERNA and it is listed on the Nasdaq exchange.
On which exchange is ERNA stock listed?
ERNA stock is listed on the Nasdaq exchange.
Is ERNA a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for ERNA, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of ERNA.
Does ERNA stock pay dividends?
ERNA does not pay a dividend.
When does ERNA stock report earnings?
ERNA will report earnings on 2025-03-12.
What is the Price/Earnings (PE) ratio of ERNA?
ERNA does not have a PE ratio as the earnings reported over the last twelve months were negative (-8.31).
What is the Short Interest ratio of ERNA stock?
The outstanding short interest for ERNA is 16.54% of its float.
ERNA Technical Analysis
ERNA Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to ERNA. ERNA has a bad profitability rating. Also its financial health evaluation is rather negative.
ERNA Financial Highlights
Over the last trailing twelve months ERNA reported a non-GAAP Earnings per Share(EPS) of -8.31. The EPS decreased by -98.75% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -582.39% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
ERNA Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 43% to ERNA. The Buy consensus is the average rating of analysts ratings from 6 analysts.